Search
Idursulfase
go.drugbank.com/drugs/DB01271ApprovedInvestigationalIdursulfase is produced by recombinant DNA technology in a human cell line. … Idursulfase is an enzyme that hydrolyzes the 2-sulfate esters of terminal iduronate sulfate residues from the glycosaminoglycans dermatan sulfate and heparan sulfate in the lysosomes of various cell types
Products: Elaprase (TM) Solution for Intravenous Infusion 2mg/ ml, ELAPRASE 2 MG/ML İNFÜZYONLUK ÇÖZELTİ HAZIRLAMAK İÇİN KONSANTRE, 1 ADETAcalabrutinib
go.drugbank.com/drugs/DB11703ApprovedInvestigationalreceived at least one prior therapy. … unmet medical need based on a surrogate endpoint.
Products: CALQUENCE 100 MG SERT KAPSÜL, 60 ADET, CALQUENCE 100 MG SERT KAPSÜL, 56 ADETBaricitinib
go.drugbank.com/drugs/DB11817ApprovedInvestigational[A248400] The EC later approved baricitinib for the treatment of atopic dermatitis, making it the first JAK inhibitor used for this indication in Europe. … [L41760] Baricitinib was first approved by the European Commission (EC) in February 2017 for the treatment of rheumatoid arthritis in adults [A248395] and was later approved by the FDA in 2018.
Products: OLUMIANT FILM-COATED TABLET 2MG, Olumiant 2mg Film-Coated TabletsGlecaprevir
go.drugbank.com/drugs/DB13879ApprovedInvestigationalThe combinations of amino acid substitutions at NS3 position Y65H and D/Q168 also results in greater reductions in glecaprevir susceptibility, and NS3 Q80R in genotype 3a patients also leads to glecaprevir … In cell cultures, the emergence of amino acid substitutions at NS3 resistance-associated positions A156 or D/Q168 in HCV genotype 1a, 2a or 3a replicons led to reduced susceptibility to glecaprevir [FDA
Mixtures: MAVİRET 100 MG/40 MG FİLM KAPLI TABLET, 84 ADET, MAVIRET® 100/40 MG TABLETAS RECUBIERTASPimavanserin
go.drugbank.com/drugs/DB05316ApprovedInvestigational[A232783] It was approved by the FDA in April 2016 for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis thanks to favorable results from a pivotal six-week, randomized … [L48236] Although the exact mechanism of action is unknown, it is thought that pimavanserin interacts with the serotonin receptors, particularly the 5-HT<sub>2A</sub> and HT<sub>2C</sub> receptors.
Taurine
go.drugbank.com/drugs/DB01956ApprovedInvestigationalNutraceuticalTaurine, whose chemical name is 2-aminoethanesulfonic acid, is one of the most abundant amino acids in several organs. It plays important role in essential biological processes. … [A31396] This conditional amino acid can be either be manufactured by the body or obtained in the diet mainly by the consumption of fish and meat.
Mixtures: SMOFKABIVEN EF, Numeta G 13 % E Emulsion zur InfusionAtovaquone
go.drugbank.com/drugs/DB01117ApprovedInvestigationalAtovaquone is a hydroxynaphthoquinone, or an analog of ubiquinone, that has antimicrobial and antipneumocystis activity. It is being used in antimalarial protocols.
Mixtures: Malarone 250 mg/100 mg Filmtabletten, Atovaquon/Proguanilhydrochlorid STADA 250 mg/100 mg FilmtablettenProducts: ATOVAQUONE E PROGUANILE SANDOZMelphalan flufenamide
go.drugbank.com/drugs/DB16627ApprovedWithdrawnIt has since been withdrawn from the market in the wake of the phase 3 OCEAN trial which showed a decrease in overall survival in comparison to standard treatment with [pomalidomide] and [dexamethasone … [A230143,L32173] Melphalan flufenamide was granted FDA approval on 26 February 2021.[L32173].
Bazedoxifene
go.drugbank.com/drugs/DB06401ApprovedInvestigationalIt is approved in the European Union (marketed in Italy and Spain) and Japan as monotherapy. … the prevention of postmenopausal osteoporosis in women.
Mixtures: DUAVIVE 20 mg/0.45 mg modified - release tablets, DUAVİVE 0.45 MG/20 MG DEĞİŞTİRİLMİŞ SALIMLI TABLET, 30 TABLETAprocitentan
go.drugbank.com/drugs/DB15059ApprovedInvestigational[L50261] It was the first antihypertensive employing a novel mechanism to be approved in almost 40 years.[L50261] … [A263386] Patients with resistant hypertension are at an increased risk of cardiovascular and renal events[A263386] and have traditionally had limited additional treatment options.